Effect of gold treatment on cytokine expression in synovium

A recent paper in this journal described the effect of intramuscular gold treatment on cytokine expression in synovial membranes from patients with rheumatoid arthritis. In that paper, the authors described changes in synovial membrane expression of interleukins (IL) II-1α, IL-1β, IL-6, and tumour necrosis factor α in patients who had received intramuscular gold treatment. However, the authors failed to mention that some of the results had been published in another journal by a similar group of authors. Neither paper is cross referenced in the other, and it is not clear from these two papers whether the authors are reporting the same set of results in two different papers.

In one paper, the authors described a significant failure rate with blind needle biopsy of the synovial membrane, which is particularly a problem with studies involving sequential biopsy as was performed in these two studies. Our experience is similar with this technique and we have now changed to performing all synovial biopsying under direct vision through a needle arthroscopy under local anaesthesia. However, despite the fact that the two patient groups appear to be similar, if not identical, in these two papers, one paper states that only seven of 18 patients recruited in the study gave three satisfactory sequential synovial biopsy specimens, while the other paper implies, though does not clearly state, that satisfactory synovial biopsy specimens were obtained in all 10 patients for all time points (0, 2, and 12 weeks). This suggests either that the authors’ biopsy technique or success rate has changed dramatically during the period between preparation of the two papers, or that additional patients were obtained to ‘make up the numbers’.

Could the authors please confirm whether:

1. The patient groups studied in these two papers are, in fact, identical.
2. The same results for IL-1β have been published in two different papers in two different journals.
3. All the patients reported in one paper provide adequate synovial biopsy specimens for all three time points and, if so, how was this possible in view of the results and discussion in the other paper from the same group.

MALCOLM D SMITH
The Arthritis Unit, Flinders Medical Centre, Bedford Park, South Australia 5042, Australia


AUTHOR’S REPLY: I would like to respond to Dr Smith’s letter as follows:

(1) The study by Kirkham et al. in the Journal of Rheumatology and the paper by Dr Yanni in the Annals indeed refer to the same patients.

(2) The paper by Kirkham studied only interleukin-1β and was the first study reporting the application of immunohistochemical techniques for cytokines to this kind of material. The paper by Dr Yanni in the Annals dealt with four additional cytokines and included additional cellular histological and other markers, particularly related to cells of the monococyte-macrophage series. It was a complete oversight on our part not to have referenced that paper in the Annals.

(3) Satisfactory synovial biopsy specimens were obtained in all 10 patients for all time points (0, 2, and 12 weeks). Some patients refused repeat biopsy or the specimens were technically inadequate; it is for these reasons that not all patients who entered the study were reported upon.

G S PANAYI
Division of Medicine, Rheumatology Unit, Guy’s Hospital, London SE1 9RT, United Kingdom

Cytoplasmic staining, ANA negative status, and ENA testing in rheumatic diseases

Koh and colleagues reported cytoplasmic immunofluorescence staining on HEP-2 cells in 75 of 1173 sera (6.4%) of patients with various rheumatic diseases referred to the Royal National Hospital for Rheumatic Diseases in Bath. Forty two of these 75 sera (56%) were antinuclear antibody (ANA) positive, and 33 ANA negative. Ten of the 75 sera (13.3%) were extractable nuclear antigen (ENA) positive by immunodiffusion (mainly SS-A and Jo-1) and five of these 10 sera were ANA negative. No association of cytoplasmic staining patterns with any specific disease was noted. However, because five of the 10 ENA positive sera were ANA negative, the authors concluded that ‘cytoplasmic staining should not be ignored as it may indicate the presence of antibodies to ENA in the absence of nuclear staining’.

We wish to question whether this conclusion is strong enough to advocate positive cytoplasmic staining as an indication for further routine testing for ENA in ANA negative patients with rheumatic diseases. In our laboratory, 5843 sera of patients with various rheumatic diseases were tested for ANA on HEP-2 cells in the past two years. Six hundred sera (10.3%) showed cytoplasmic staining, which is comparable to the 6.4% in Bath. Two hundred and ninety five of those 600 sera with cytoplasmic staining were randomly tested further for ENA by immunodiffusion: 32 (10.8%) were ENA positive (mainly SS-A and SS-B), which is similar to the 13.3% in Bath.

Of the 600 sera with cytoplasmic staining, 179 were ANA positive (29.8%). This percentage is clearly less than that observed in Bath, where ANA positive sera were also observed among ANA negative sera. Thus, cytoplasmic staining in ANA negative sera, which were not noted in the study by Koh et al., was clearly less frequent than in ANA positive sera, which was noted in this study. This may indicate that cytoplasmic staining should not be ignored as it may indicate the presence of antibodies to ENA in the absence of nuclear staining.

Authors’ Reply: Further to our data, Dr Lems and colleagues provide evidence that a positive anti-ENA may occur in sera that are negative for anti-cytoplasmic and for anti-nuclear antibodies on routine indirect immunofluorescence of HEP-2 cells. We have not tested a sufficient number of such sera ourselves to assess the relative chance of detecting a positive ENA in the absence of nuclear or cytoplasmic staining. However, we still maintain that cytoplasmic staining may indicate the presence of anti-ENA, especially considering the predominantly cytoplasmic distribution of autoantibodies such as Jo-1 (histidyl-RNA binding antigen). Perhaps the clinical importance for clinicians is that a negative ANA on immunofluorescence should not preclude further serological testing for autoantibodies when clinically indicated.

WEI HOWE KOH
Bath Institute for Rheumatic Diseases, Bath BA1 1HD, United Kingdom

NEIL JOHN McHUGH
Royal National Hospital for Rheumatic Diseases, Bath BA1 1RL, United Kingdom
Authors' reply

Wei Howe Koh and Neil John McHugh

doi: 10.1136/ard.54.9.779-d

Updated information and services can be found at:
http://ard.bmj.com/content/54/9/779.4.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/